Floatz Rating
B58/100
Confidence
Indicative
Sponsor
I-Mab Biopharma US Limited
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07432295CT.gov Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | — | Recruiting | — | — | — |
NCT07140393CT.gov A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | — | Not Yet Recruiting | — | — | — |
NCT06761417CT.gov A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults | — | Recruiting | — | — | — |
NCT06621563CT.gov Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06632262CT.gov A Phase 2 Clinical Study of ABSK061 and ABSK043 | — | Recruiting | — | — | — |
NCT06504732CT.gov To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | — | Recruiting | — | — | — |
NCT06275958CT.gov DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06255392CT.gov Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT06041035CT.gov A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
Show 44 more trialsShow fewer
NCT05954078CT.gov Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer | — | Recruiting | — | — | — |
NCT04607421CT.gov A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04569916CT.gov Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | — | Unknown | — | — | — |
NCT04522284CT.gov PRECISE CURATE.AI Pilot Clinical Trial | — | Unknown | — | — | — |
NCT04802980CT.gov A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | — | Unknown | — | — | — |
NCT04165772CT.gov Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | — | Recruiting | — | — | — |
NCT04080843CT.gov Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | — | Completed | — | — | — |
NCT03775525CT.gov Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | — | Unknown | — | — | — |
NCT03781362CT.gov Study of CPI-100 in Patients With Advanced Tumors | — | Completed | — | — | — |
NCT03641547CT.gov M6620 Plus Standard Treatment in Oesophageal and Other Cancer | — | Completed | — | — | — |
NCT03544723CT.gov Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | — | Unknown | — | — | — |
NCT02932280CT.gov Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | — | Active Not Recruiting | — | — | — |
NCT02861300CT.gov CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | — | Completed | — | — | — |
NCT02715531CT.gov A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | — | Completed | — | — | — |
NCT03006614CT.gov PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT02593708CT.gov Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | — | Terminated | — | — | — |
NCT02304419CT.gov A Study of Galunisertib on the Immune System in Participants With Cancer | — | Completed | — | — | — |
NCT02423343CT.gov A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02648425CT.gov Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | — | Completed | — | — | — |
NCT02435927CT.gov ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin | — | Unknown | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01917279CT.gov Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC | — | Unknown | — | — | — |
NCT02025803CT.gov A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01705002CT.gov Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | — | Completed | — | — | — |
NCT01373164CT.gov A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | — | Completed | — | — | — |
NCT01315431CT.gov A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors | — | Unknown | — | — | — |
NCT01463982CT.gov Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT01369433CT.gov A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols | — | Terminated | — | — | — |
NCT01050322CT.gov Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. | — | Completed | — | — | — |
NCT00920868CT.gov XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | — | Completed | — | — | — |
NCT00838539CT.gov Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00807859CT.gov Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00811993CT.gov A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00397046CT.gov A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00390676CT.gov A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine | — | Completed | — | — | — |
NCT00300781CT.gov Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00454649CT.gov Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | — | Completed | — | — | — |
NCT00618124CT.gov A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together | — | Completed | — | — | — |
NCT00354523CT.gov Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma | — | Terminated | — | — | — |
NCT00207129CT.gov Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT02494596CT.gov A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00249977CT.gov Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan | — | Completed | — | — | — |
NCT00052273CT.gov LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02354612CT.gov Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | I-Mab Biopharma US Limited | P3 | B · 58 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →